Global Transthyretin Amyloidosis Treatment Market Insights Forecasts to 2033.

• The Global Transthyretin Amyloidosis Treatment Market Size was Valued at USD 5.52 Billion in 2023.
• The Market Size is Growing at a CAGR of 6.56% from 2023 to 2033.
• The Worldwide Transthyretin Amyloidosis Treatment Market Size is Expected to Reach USD 10.42 Billion by 2033.
• Middle East and Africa are Expected to Grow the fastest during the forecast period.

The Global Transthyretin Amyloidosis Treatment Market Size is Anticipated to Exceed USD 10.42 Billion by 2033, Growing at a CAGR of 6.56% from 2023 to 2033.  

Market Overview

Transthyretin Amyloidosis is a rare and progressive disease characterized by the deposition of abnormal proteins such as misTTR in organs and tissue of the body characterized by the alteration in the structure of transthyretin, which leads to the impairment of tetramers formation. Patients suffering from transthyretin amyloidosis show the symptoms of carpel syndrome for arms, lumbar spinal stenosis for the back, vitreous opacities for the head and neck, and swelling at the feet. Mutated/ hereditary ATTR and wild-type ATTR are the two major types of transthyretin amyloidosis. The autonomic nervous system, which controls involuntary body functions such as blood pressure, heart rate, and digestion, may also be affected by amyloidosis. Sometimes major organs of the body such as the liver, kidney, nerves, and heart are affected by transthyretin amyloidosis. Protein deposits in these nerves result in a loss of sensation or muscle weakness in the extremities (peripheral neuropathy). Other areas of amyloidosis include the heart, kidneys, eyes, and gastrointestinal tract. Cardiac form of transthyretin amyloidosis is more common among the African ancestry people. The extensive research for the development of new therapies and drugs for the treatment of transthyretin growing the global transthyretin amyloidosis market.

Report Coverage

This research report categorizes the market for the global transthyretin amyloidosis treatment market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global transthyretin amyloidosis treatment market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the global transthyretin amyloidosis treatment market.

Driving Factors

The increasing prevalence of transthyretin amyloidosis especially in the geriatric population leads to growing market demand for transthretin amyloidosis due to the growing geriatric population rate at 16% which is expected to reach 1.5 billion in 20250. Around 50,000 people are living with hATTR amyloidosis and about 400,000 people live with ATTRwt amyloidosis worldwide as per the Prothena article. According to the NCBI data, an age-related form of amyloidosis that is wild-type ATTR primarily affects the heart. Aging is a substantial risk factor for the wild type of amyloidosis (ATTRwt). Several initiatives have encouraged awareness regarding the transthyretin amyloidosis disease and its treatment. For instance, the Australian Amyloidosis Network organized a biennial touring workshop to raise awareness among health professionals and patients with ATTR amyloidosis.  

Restraining Factors

The lack of awareness among healthcare professionals leads to inappropriate treatment of patients impeding the transthyretin amyloidosis treatment market. The high costs of newly launched drugs are projected to hamper the market. For instance, the cost of the newly approved drug Patisiran is about USD 450,000 as per report of Alnylam Pharmaceuticals, Inc. Another drug, Inotersen, is worth USD 450,000 yearly. 

Market Segmentation

The Global Transthyretin Amyloidosis Treatment Market share is classified into type, therapy, disease type, and distribution channel.

• The ATTR-CM segment is expected to hold the largest share of the global transthyretin amyloidosis treatment market during the forecast period.   

Based on the type, the global transthyretin amyloidosis treatment market is divided into TTR-PN, and ATTR-CM. Among these, the ATTR-CM segment is expected to hold the largest share of the global transthyretin amyloidosis treatment market during the forecast period. Various autopsy studies suggest that 22-25% of people aged 80 years and above reported TTR amyloid deposition in the heart. Transthyretin amyloidosis (ATTR-CM) occurs when liver produces faulty transthyretin (TTR) proteins. Drugs such as Tafamidis (Vyndaqel®, Vyndamax®) and Diflunisal (Dolobid®), a nonsteroidal anti-inflammatory drug (NSAID) that providers may use as an off-label treatment. 

• The targeted therapy segment is expected to grow at the fastest pace in the global transthyretin amyloidosis treatment market during the forecast period.    

Based on the therapy, the global transthyretin amyloidosis treatment market is divided into targeted, supportive, and pipeline. Among these, the targeted therapy segment is expected to grow at the fastest pace in the global transthyretin amyloidosis treatment market during the forecast period. Drugs such as Onpattro, Inotersen, and Tafamidis. Onpattro targets the production of TTR protein. The approval of these drug-associated therapies globally fuels the segment's growth. The high prescription and cost value of drugs are the significant factors for fueling the market of targeted therapy of transthyretin amyloidosis. The rising awareness regarding the available drug therapies leads to increasing demand for these drug for the treatment of transthyretin amyloidosis patients. The rising initiatives by key market players for developing and manufacturing targeted drugs are likely to grow the market.  

• The hereditary transthyretin segment is expected to grow at the greatest pace in the global transthyretin amyloidosis treatment market during the forecast period.

Based on the disease type, the global transthyretin amyloidosis treatment market is divided into hereditary transthyretin amyloidosis, and wild-type amyloidosis. Among these, the hereditary transthyretin segment is expected to grow at the greatest pace in the global transthyretin amyloidosis treatment market during the forecast period. Patisiran, Vutrisiran, Inotersen, and Eplontersen are approved by the US Food and Drug Administration (FDA) for the treatment of polyneuropathy caused by hereditary transthyretin-related amyloidosis (hATTR) in adults. The growing development of drugs and several drugs by pharmaceutical companies overcome the disease of hereditary transthyretin-mediated amyloidosis.

• The hospital pharmacies segment is expected to grow at the greatest pace in the global transthyretin amyloidosis treatment market during the forecast period.

Based on the distribution channel, the global transthyretin amyloidosis treatment market is divided into hospital pharmacies, specialty pharmacies, retail pharmacies, and online pharmacies. Among these, the hospital pharmacies segment is expected to grow at the greatest pace in the global transthyretin amyloidosis treatment market during the forecast period. The establishment of the Amyloidosis program offers access to innovative therapies, patient-centered care, and new clinical trials leading to driving the market in the hospital pharmacy segment. The rising initiatives for educating physicians and patients and spreading awareness among the patients regarding transthyretin amyloidosis treatment.  

Regional Segment Analysis of the Global Transthyretin Amyloidosis Treatment Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the global transthyretin amyloidosis treatment market over the predicted timeframe.

North America is anticipated to hold the largest share of the global transthyretin amyloidosis treatment market over the predicted timeframe. The rising drug prescription for treating transthyretin amyloidosis, and higher treatment rates are the significant factors responsible for propelling the transthyretin amyloidosis treatment market. The approval of the drug ONPATTRO by Health Canada for treating hATTR polyneuropathy positively affected the regional market of transthyretin amyloidosis treatment.

The Middle East and Africa region is expected to grow at the fastest pace in the global transthyretin amyloidosis treatment market during the forecast period. The rising prevalence of disease and increasing approval rate in the region are likely to enhance the market growth.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the global transthyretin amyloidosis treatment along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Pfizer Inc.
• AstraZeneca
• Johnson & Johnson Services, Inc.
• SOM Biotech
• Astellas Pharma, Inc.
• Acrotech Biopharma
• Ionis Pharmaceuticals, Inc.
• Alnylam Pharmaceuticals, Inc.
• Prothena
• BridgeBio Pharma, Inc.
• Bristol-Myers Squibb Company
• Abbvie, Inc.
• BELLUS Health Inc.
• Eidos Therapeutics
• Bausch Health Company
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In June 2022, Alnylam announced FDA approval of AMVUTTRA (Vutrisiran), an RNAi therapeutics for the treatment of the Polyneuropathy of Hereditary Transthyretin-mediated Amyloidosis in adults. AMVUTTRA (Vutrisiran) is the first and only FDA-approved treatment demonstrating reversal in Neuropathy impairment with subcutaneous administration once every 3 months.

• In January 2022, AstraZeneca announced Orphan Drug Designation for Eplontersen in the US. Eplontersen is an investigational antisense medicine designed to treat transthyretin amyloidosis (ATTR), a systemic, progressive, and fatal disease. The medicine helps to reduce the production of transthyretin (TTR protein) for the treatment of both hereditary and non-hereditary forms of ATTR. 

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the Global Transthyretin Amyloidosis Treatment Market based on the below-mentioned segments: 

Global Transthyretin Amyloidosis Treatment Market, By Type

• ATTR-PN
• ATTR-CM

Global Transthyretin Amyloidosis Treatment Market, By Therapy

• Targeted
• Supportive
• Pipeline

Global Transthyretin Amyloidosis Treatment Market, By Disease Type

• Hereditary transthyretin amyloidosis
• Wild-type amyloidosis

Global Transthyretin Amyloidosis Treatment Market, By Distribution Channel

• Hospital Pharmacies
• Specialty pharmacies
• Retail pharmacies
• Online pharmacies

Global Transthyretin Amyloidosis Treatment Market, By Region

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • Uk
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa